Propanidid
| 250px | |
| Propanidid
| |
| Systematic (IUPAC) name | |
| propyl 2-[4-(diethylcarbamoylmethoxy)-3-methoxy- phenyl]acetate | |
| Identifiers | |
| CAS number | |
| ATC code | N01 |
| PubChem | |
| Chemical data | |
| Formula | C18H27NO5 |
| Mol. mass | 337.411 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Propanidid is an ultra short-acting phenylacetate general anesthetic. It was originally introduced by Bayer but anaphylactic reactions caused it to be withdrawn shortly afterwards.
Even though Cremophor EL has been shown to cause anaphylactic reactions in humans in several cases (both when given intraveneosly and orally), it is still debated whether or not propanidid itself may have contributed to the reactions.
It has been argued that the toxic effects or reactions to Propanidid (and Althesin) were due to the drugs themselves [1]. Several cases of negative reactions have been recorded for different drugs using Cremophor EL as solubilizer. This suggest that the negative reactions were mainly caused by Cremophor and not by the drug substances themselves.
References
- ↑ A new Steroid Anaesthetic - Althesin (pdf). PubMed. Retrieved on 2007-01-07. See page 1/49
External links
- Klockgether-Radke A, Kersten J, Schröder T, Stafforst D, Kettler D, Hellige G (1995). "Anesthesia with propanidid in a liposomal preparation. An experimental study in swine". Anaesthesist 44 (8): 573-80. PMID 7573906.
- Habazettl H, Vollmar B, Röhrich F, Conzen P, Doenicke A, Baethmann A (1992). "Anesthesiologic efficacy of propanidid as a liposome dispersion. An experimental study with rats". Anaesthesist 41 (8): 448-56. PMID 1524155.
- Zawisza P, Przyborowski L (1992). "Propanidid and etomidate identification from the blood by thin-layer chromatography". Acta Pol Pharm 49 (5-6): 15-7. PMID 16092193.
- Theis JG, et al. "Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL". Journal of Clinical Oncology] 13: 2508-2516.
- Ebo DG, et al. "IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine". Annals of Allergy, Asthma and Immunology 87 (3): 243-245.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies